Please assess the completion status of the following clinical trial:

Trial Title: REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Single, first clinical event suggestive of MS within 60 days prior to study Day 1, which is the day of randomization (clock starts 24 hours after onset). The event must be a new neurological abnormality present for at least 24 hours, either mono- or polysymptomatic, other than a paresthesia, vegetative or cerebral dysfunction~* At least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 millimeter (mm), at least one of which is ovoid or periventricular or infratentorial~* EDSS 0 - 5.0 at least one time point during the screening period before start of treatment~* 18 and 50 years old, inclusive~* Willing to follow study procedures~* Written informed consent~* If female, subject must:~  * be neither pregnant nor breast-feeding nor attempting to conceive~ * use a highly effective method of contraception. A highly effective method of contraception is defined as those which result in a low failure rate (that is \[i.e.\] less than 1 percent \[%\] per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner~Exclusion Criteria:~* Diagnosis of MS (per McDonald criteria 2005)~* Any other disease that could better explain the subject's signs and symptoms~* Complete transverse myelitis or bilateral optic neuritis~* Subject uses or has used any other approved MS disease-modifying drug (DMD)~* Any investigational drug or undergone an experimental procedure within 12 weeks prior to study Day 1~* Oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 30 days prior to study Day 1~* Total bilirubin greater than 2.5 times upper limit of normal (ULN)~* Subject has total aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase (ALP) greater than 2.5 times the ULN~* Inadequate bone marrow reserve, defined as a total white blood cell count less than 3.0 x 109 per liter (/L), platelet count less than 75 x 109/L, hemoglobin less than 100 gram per liter (g/L)~* Current autoimmune disease~* Major medical or psychiatric illness (including history of or current severe depressive disorders and/or suicidal ideation) that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol~* History of seizures not adequately controlled by treatment~* Cardiac disease, such as angina, congestive heart failure or arrhythmia~* Known allergy to IFN-beta or the excipient(s) of the study medication~* Any condition that could interfere with the MRI evaluation;~* Known allergy to gadolinium-diethylene triamine pentaacetic acid (DTPA)~* Previously participated in this study~* Participated in any clinical trial within the past 6 months~* Any immunomodulatory or immunosuppressive therapy at any time prior to enrollment, including, but not limited to, the following products: any IFN, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (e.g. natalizumab, alemtuzumab/Campath, anti-cluster of differentiation 4 \[CD4\]), intravenous, immunoglobulins (Igs), cytokines or anti-cytokine therapy~* Any experimental MS treatment prior to trial entry, including, but not limited to, any statins (if given to prevent MS) and pentoxyfylline~* History of alcohol or drug abuse~* Intolerance or any contraindication to both paracetamol (acetaminophen) and ibuprofen~* Inability to administer subcutaneous injections either by self or by caregiver~* Moderate to severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- RNF 44 mcg three times weekly (Type: ACTIVE_COMPARATOR): None
- RNF 44 mcg once weekly and placebo twice weekly for blinding (Type: ACTIVE_COMPARATOR): None
- Placebo three times weekly (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).